Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
Provided By GlobeNewswire
Last update: Aug 12, 2024
Significant progress addressing CMC items noted in CRL
BLA resubmission remains on track for 2H 2024
CLEVELAND, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2024 and recent corporate progress.
Read more at globenewswire.comNASDAQ:ABEO (2/21/2025, 8:00:00 PM)
5.78
-0.04 (-0.69%)
Find more stocks in the Stock Screener
